Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
PHASE2
This trial is Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patien...
Status
Active Not Recruiting
Location
Yonsei University Health System, Severance Hospital
Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)
PHASE2
* In this study, we hypothesized that immune engagement by amivantamab will...
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PHASE2
The primary purpose of the study is to assess how well amivantamab in combi...